Targeting Vitamin D Deficiency to Limit Exacerbations in Respiratory Diseases: Utopia or Strategy With Potential?
Exacerbations
Lung
Vitamin D
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
13
05
2019
accepted:
18
07
2019
pubmed:
28
7
2019
medline:
9
6
2021
entrez:
28
7
2019
Statut:
ppublish
Résumé
Patients with respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease, or asthma often experience an acute worsening of respiratory symptoms, termed exacerbations. Although the course of exacerbations is disease specific, they are mostly triggered by a respiratory infection. Exacerbations often require hospitalization and are an important cause of mortality. Treatments of exacerbations aim to minimize the negative impact and to prevent subsequent events. Despite many existing therapy options, many patients do not benefit from therapy and suffer from recurrent events. Vitamin D deficiency is a worldwide problem and is extremely prevalent in these patients. Vitamin D, known for its calcemic effects, also has immunomodulatory and anti-infectious actions and can therefore be a possible agent to treat or prevent exacerbations. This review will focus on vitamin D as a potential candidate to treat or prevent exacerbations in CF, COPD, and asthma.
Identifiants
pubmed: 31350569
doi: 10.1007/s00223-019-00591-4
pii: 10.1007/s00223-019-00591-4
doi:
Substances chimiques
Vitamins
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM